Wall Street analyst estimates for Kiniksa Pharmaceuticals International, plc (KNSA): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2028E | $1.6B | $1.5B – $1.6B | $2.90 | 6 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 11 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-23 | $0.25 | ||
| 2026-10-27 | $0.56 | $0.37 | +50.9% |
| 2026-07-28 | $0.30 | $0.30 | +0.2% |
| 2026-04-28 | $0.27 | $0.18 | +50.0% |
| 2026-02-24 | $0.17 | $0.29 | -41.4% |
| 2025-10-28 | $0.23 | $0.33 | -30.3% |
| 2025-07-29 | $0.23 | $0.18 | +27.8% |
| 2025-04-29 | $0.11 | $0.02 | +450.0% |
Valuation Ratios
| P/E Ratio | 71.21 |
| Price / Book | 10.27 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M |
| Cost of Revenue | $22,000 | $28,000 | $286,000 | $3.3M | $3.8M | $9.1M | $22.9M | $56.5M | $60.9M | $307.4M |
| Gross Profit | -$22,000 | -$28,000 | -$286,000 | -$3.3M | -$3.8M | $29.4M | $197.3M | $213.7M | $362.3M | $370.1M |
| Research & Development | $17.4M | $56.4M | $86.6M | $132.9M | $109.6M | $99.3M | $65.5M | $76.1M | $111.6M | $96.9M |
| Selling, General & Admin | $6.6M | $9.0M | $21.6M | $33.8M | $43.9M | $85.9M | $98.0M | $129.4M | $168.0M | $196.3M |
| Operating Expenses | $24.0M | $65.4M | $108.2M | $166.7M | $153.6M | $186.1M | $187.5M | $238.9M | $407.9M | $292.9M |
| Operating Income | -$24.0M | -$65.4M | -$108.2M | -$170.0M | -$157.4M | -$156.6M | $9.8M | -$25.2M | -$45.6M | $77.2M |
| EBITDA | -$24.0M | -$65.4M | -$107.9M | -$161.8M | -$153.8M | -$154.2M | $13.4M | -$14.3M | -$34.5M | $90.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$23.9M | -$64.9M | -$103.4M | -$163.9M | -$156.2M | -$156.5M | $11.0M | -$16.7M | -$36.2M | $88.9M |
| Income Tax | $36,000 | $2,000 | -$214,000 | -$2.0M | $5.2M | $1.4M | -$172.3M | -$30.7M | $7.0M | $29.9M |
| Net Income | -$24.0M | -$64.9M | -$103.2M | -$161.9M | -$161.4M | -$157.9M | $183.4M | $14.1M | -$43.2M | $59.0M |
| EPS | -$0.74 | -$2.00 | -$3.49 | -$2.99 | -$2.61 | -$2.30 | $2.64 | $0.20 | -$0.60 | $0.80 |
| EPS (Diluted) | -$0.74 | -$2.00 | -$3.49 | -$2.99 | -$2.61 | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 |
| Shares Outstanding (Diluted) | 32.5 M | 32.5 M | 29.5 M | 54.0 M | 61.8 M | 68.6 M | 70.4 M | 71.9 M | 71.4 M | 79.0 M |
Price
| Price | $93.29 (closing price, November 3, 2026) |
| Market Cap | $7.3B |
| Exchange | NASDAQ |
| Country | GB |
Related companies: IMVT · DNTH · SYRE · ORKA · NRIX
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of KNSA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks